Patents by Inventor Osnat Bohana-Kashtan

Osnat Bohana-Kashtan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RPE CELL POPULATIONS AND METHODS OF GENERATING SAME
    Publication number: 20180016553
    Abstract: A population of human polygonal RPE cells is disclosed. At least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms. Methods of generating same are also disclosed.
    Type: Application
    Filed: December 30, 2015
    Publication date: January 18, 2018
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • ASSESSING RETINAL PIGMENT EPITHELIAL CELL POPULATIONS
    Publication number: 20180011092
    Abstract: A method of qualifying whether a cell population is a suitable therapeutic for treating an eye condition is disclosed. The method comprises analyzing co-expression of premelanosome protein (PMEL17) and at least one polypeptide selected from the group consisting of cellular retinaldehyde binding protein (CRALBP), lecithin retinol acyltransferase (LRAT) and sex determining region Y-box 9 (SOX 9) in the population of cells.
    Type: Application
    Filed: December 30, 2015
    Publication date: January 11, 2018
    Inventors: Osnat Bohana-Kashtan, Lior Ann Rosenberg Belmaker, Ofer Wiser
  • METHODS OF TREATING RETINAL DISEASES
    Publication number: 20180008458
    Abstract: A method of treating a subject with dry-form age-related macular degeneration (AMD) is disclosed. The method comprises administering into the subretina of the subject a therapeutically effective amount of a pharmaceutical composition comprising human RPE cells, wherein at least 95% of the cells thereof co-express premelanosome protein (PMEL17) and cellular retinaldehyde binding protein (CRALBP), wherein the trans-epithelial electrical resistance of the cells is greater than 100 ohms to the subject, thereby treating the subject.
    Type: Application
    Filed: April 30, 2015
    Publication date: January 11, 2018
    Inventors: Eyal Banin, Benjamin Eithan Reubinoff, Osnat Bohana-Kashtan, Nir Netzer, Charles Sherard Irving